- In September 2024, Translumina Therapeutics, a prominent coronary stent provider, announced the launch of its operations in the UAE. This move follows their collaboration with the esteemed German Heart Centre to develop advanced drug-eluting stent technologies, including the most extensively studied DES globally, backed by over a decade of research on safety and efficacy
- In July 2024, MicroPort Scientific Corporation revealed that its subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., obtained market approval from the NMPA for Firesorb, the first next-generation fully bioresorbable cardiac stent. Pre-market studies indicated that Firesorb demonstrated performance comparable to that of permanent drug-eluting stents in key clinical metrics, such as success rates and late lumen loss
- In May 2024, Global healthcare leader Abbott announced the introduction of the XIENCE Sierra, an everolimus-eluting coronary stent system, in India. This launch followed the system's regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in February of the same year
- In May 2022, Medtronic plc, a global frontrunner in healthcare technology, announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Onyx Frontier drug-eluting stent (DES). This stent represents the latest advancement in the Resolute DES family, utilizing the same best-in-class platform as the Resolute Onyx DES, but with an improved delivery system designed to enhance deliverability and performance in challenging cases
- In October 2021, The InspireMD CGuard Embolic Prevention Stent System (EPS) received reimbursement approval in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) for the treatment of carotid artery disease (CAD) and stroke prevention
Frequently Asked Questions
The market is segmented based on Global Metal Stent Market Segmentation, By Product Type (Coronary Stents and Peripheral Vascular Stents), Technology (Bare Metal, Drug Eluting, and Bioreabsorbable), End User (Hospitals, Ambulatory Surgical Centres, and Others) – Industry Trends and Forecast to 2032
.
The Global Metal Stents Market size was valued at USD 6.44 USD Billion in 2024.
The Global Metal Stents Market is projected to grow at a CAGR of 7.1% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
